Manager TitleAgeSince
Chief Executive Officer 55 -
Chief Tech/Sci/R&D Officer - 31/05/2021
Chief Operating Officer 59 23/05/2024
Director TitleAgeSince
Chairman 55 -
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/01/24 Free

Chief Technology Officer

480,319 0.3621%
31/01/24 Free

Director

200,000 0.1508%
31/01/24 Free

Director

200,000 0.1508%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-.--% - - 2.62M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.31%+0.05%+36.79%+180.14% 45B
Weighted average by Cap. -0.83%+0.20%+36.63%+155.25%
Logo Gamida Cell Ltd.
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Employees
147
  1. Stock Market
  2. Stocks
  3. GMDA Stock